What is a biosimilar? How do biosimilars contribute to affordable healthcare, and what are the key barriers to their large-scale adoption in India? Suggest reforms to make Indian biosimilars globally competitive.
Kartavya Desk Staff
Topic: Awareness in the fields of IT, Space, Computers, robotics, nano-technology, bio-technology
Topic: Awareness in the fields of IT, Space, Computers, robotics, nano-technology, bio-technology
Q5. What is a biosimilar? How do biosimilars contribute to affordable healthcare, and what are the key barriers to their large-scale adoption in India? Suggest reforms to make Indian biosimilars globally competitive. (15 M)
Difficulty Level: Medium
Reference: TH
Why the question? Biosimilars are emerging as a crucial alternative to expensive biologics, yet India faces regulatory and market challenges in scaling their adoption. Addressing these barriers is essential for affordable healthcare and global competitiveness. Key demand of the question The question demands an understanding of biosimilars, their role in making healthcare affordable, the challenges hindering their large-scale adoption in India, and necessary reforms to enhance India’s global position in the biosimilar market. Structure of the Answer Introduction: Define biosimilars concisely, highlighting their distinction from traditional generics and their significance in modern healthcare. Briefly mention India’s potential in biosimilar production. Body: What is a biosimilar? Explain the scientific basis of biosimilars, their manufacturing process, and their regulatory framework compared to generics. How do biosimilars contribute to affordable healthcare? Discuss cost reduction, market competition, impact on out-of-pocket healthcare expenditure, and their role in public health schemes. What are the key barriers to their large-scale adoption in India? Highlight regulatory gaps, high development costs, awareness issues, and legal hurdles from multinational companies. Suggest reforms to make Indian biosimilars globally competitive. Recommend a robust legal framework, faster approval mechanisms, financial incentives for R&D, and awareness programs. Conclusion: Summarize the need for a comprehensive biosimilar policy and proactive government intervention to position India as a leader in affordable biologics, ensuring both accessibility and economic growth.
Why the question?
Biosimilars are emerging as a crucial alternative to expensive biologics, yet India faces regulatory and market challenges in scaling their adoption. Addressing these barriers is essential for affordable healthcare and global competitiveness.
Key demand of the question
The question demands an understanding of biosimilars, their role in making healthcare affordable, the challenges hindering their large-scale adoption in India, and necessary reforms to enhance India’s global position in the biosimilar market.
Structure of the Answer
Introduction: Define biosimilars concisely, highlighting their distinction from traditional generics and their significance in modern healthcare. Briefly mention India’s potential in biosimilar production.
• What is a biosimilar? Explain the scientific basis of biosimilars, their manufacturing process, and their regulatory framework compared to generics.
• How do biosimilars contribute to affordable healthcare? Discuss cost reduction, market competition, impact on out-of-pocket healthcare expenditure, and their role in public health schemes.
• What are the key barriers to their large-scale adoption in India? Highlight regulatory gaps, high development costs, awareness issues, and legal hurdles from multinational companies.
• Suggest reforms to make Indian biosimilars globally competitive. Recommend a robust legal framework, faster approval mechanisms, financial incentives for R&D, and awareness programs.
Conclusion: Summarize the need for a comprehensive biosimilar policy and proactive government intervention to position India as a leader in affordable biologics, ensuring both accessibility and economic growth.